
    
      The primary objective of this phase 2 study is to assess objective response rate of SHR-1210
      combined with Apatinib in patients with relapsed or refractory NK/T cell lymphoma. The
      secondary objective is to observe time to response,progression free survival rate at 2
      years,overall survival rate at 2 yearsï¼Œsafety and immunogenicity of SHR-1210 combined with
      Apatinib in relapsed or refractory NK/T cell lymphoma.
    
  